comparemela.com

Latest Breaking News On - Mammaprint - Page 1 : comparemela.com

Agendia, Inc : Agendia Research Shows Highest Risk MammaPrint Category Predicts Strongest Chemosensitivity in Women with Early-Stage HR+HER2- Breast Cancer

At the 2023 ASCO® Annual Meeting, Agendia will present data that demonstrates women within MammaPrint's highest risk category have the strongest sensitivity to chemotherapy and more aggressive tumor

United statesKerry harringtonWilliam audehPeter beitschAgendia mammaprintDallas surgical groupAgendia incAnnual meetingHigh riskUltra lowChief medical officerPrint indexMammaprint high riskSurgical oncologistDallas surgicalMammaprint high

Agendia Level 1B Evidence Shows MammaPrint is the First and Only FDA-cleared Gene Expression Profiling Test to Predict Benefit from Extended Endocrine Therapy in Early-Stage Breast Cancer Patients

Late-breaking abstract at the 2022 San Antonio Breast Cancer Symposium (SABCS) will illustrate MammaPrint's ability to identify strongest candidates for extended endocrine therapy among HR+HER2-

Kostenloser wertpapierhandelGerrit jan liefersKerry harringtonAgendia incProfessor of laboratory medicineAntonio breast cancer symposiumLaboratory medicineApplied genomicsCalifornia san franciscoHelen diller family comprehensive cancer centerMammaprint low riskMammaprint high riskMammaprint ultralow riskGeriatric oncology groupLeiden university medical center

Agendia, Inc : Agendia Demonstrates Accessibility and Affordability of MammaPrint and BluePrint in Europe at ESMO Breast Cancer 2022

Next-generation sequencing version of MammaPrint and BluePrint enables decentralized testing in CE-mark jurisdictions like Germany Analysis for Belgian Health Care Package shows MammaPrint yields

United statesAnnuska glasPino cusumanoTerri clevengerAnalysis for belgian health care packageHealth care packageDrug administrationBelgian health care packageAgendia incLaboratory developed testCentre hospitalier chrEuropean society for medical oncologyBreast cancer congressBusiness developmentEuropean societyMedical oncology

Agendia, Inc : Agendia to Provide First Digital MammaPrint Capability to Brazil

AI solution will expand Agendia's testing platform in the Brazilian breast cancer market Digital MammaPrint offers fast turnaround time to molecular diagnostics, delivering actionable information

Mike cavanaughWilliam audehMark straleyAgendia mammaprintTerri clevengerDavid klimstraAgendia incDigital mammaprintChief executive officerPaige platformChief medical officerCancer mortalityYoung womenAgendia investors

Agendia, Inc : Analysis Presented at SABCS 2021 Confirms MammaPrint and BluePrint Predict Outcomes Following Neoadjuvant Chemotherapy

Data signal importance of serial genomic testing in order to appropriately adjust breast cancer treatment plans Agendia, Inc., a world leader in precision oncology for breast cancer, today shared

William audehAlicep chungTerri clevengerAgendia incSinai medical centerDepartment of surgeryDivision of surgical oncologyAntonio breast cancer symposiumCedars sinai medicalMammaprint high riskMammaprint low riskHigh riskSurgical oncologyLow riskChief medical officerMammaprint risk

vimarsana © 2020. All Rights Reserved.